NY A 2359
in committeeRelates to modifications and exceptions to case payment reimbursement rates for neoplastic disease care hospitals
New York · 2025-2026 Regular Session · lower
Quick answers
Did NY A 2359 pass?
Not yet. NY A 2359 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO HEALTH
What is NY A 2359 about?
Provides per diem rates of payment by governmental agencies for inpatient services provided by facilities designated by the federal department of health and human services as exempt extended neoplastic disease care hospitals.
Who sponsors NY A 2359?
Amy Paulin is the primary sponsor of NY A 2359, joined by 1 cosponsor.
Description
Provides per diem rates of payment by governmental agencies for inpatient services provided by facilities designated by the federal department of health and human services as exempt extended neoplastic disease care hospitals.
- Introduced
- —
- Latest action
- 2026-01-07 — REFERRED TO HEALTH
- Bill type
- bill
- Last updated
- —
Sponsors
- Amy Paulinprimary
- Michael Benedettocosponsor
Committees
Not provided by source.
Action timeline
2025-01-16
REFERRED TO HEALTH
referral-committee
2026-01-07
REFERRED TO HEALTH
referral-committee
Versions
- A2359Compare
Documents
Votes
Not provided by source.
Related bills
- Prior session: A 8883not in this corpus
- Companion bill: S 3195
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 2359. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.